Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 894

1.

Pharmacodynamical Effects of Orally Administered Exenatide Nanoparticles Embedded in Gastro-resistant Microparticles.

Soudry-Kochavi L, Naraykin N, Di Paola R, Gugliandolo E, Peritore A, Cuzzocrea S, Ziv E, Nassar T, Benita S.

Eur J Pharm Biopharm. 2018 Oct 17. pii: S0939-6411(18)30894-4. doi: 10.1016/j.ejpb.2018.10.013. [Epub ahead of print]

PMID:
30342089
2.

Exenatide implant therapy in diabetes.

Kalra S, Saboo B.

J Pak Med Assoc. 2018 Oct;68(10):1538-1540.

3.

Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial.

Yin TT, Bi Y, Li P, Shen SM, Wang WM, Jiang C, Gao CX, Wang Y, Gao LJ, Zhu DL, Feng WH.

Nutr Metab (Lond). 2018 Oct 1;15:67. doi: 10.1186/s12986-018-0295-6. eCollection 2018.

4.

Exenatide corrects postprandial hyperglycaemia in youth with cystic fibrosis and impaired glucose tolerance: a crossover randomised trial.

Geyer MC, Sullivan T, Tai A, Morton J, Edwards S, Martin AJ, Perano SJ, Gagliardi L, Rayner CK, Horowitz M, Couper JJ.

Diabetes Obes Metab. 2018 Sep 26. doi: 10.1111/dom.13544. [Epub ahead of print]

PMID:
30259623
5.

Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone.

Riswold K, Flynn V.

JAAD Case Rep. 2018 Sep 18;4(8):830-832. doi: 10.1016/j.jdcr.2018.06.009. eCollection 2018 Sep. No abstract available.

6.

Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals.

LaRue S, Springer J, Noderer M, Meehan J, Wysham CH.

J Diabetes Sci Technol. 2018 Sep 20:1932296818798376. doi: 10.1177/1932296818798376. [Epub ahead of print]

PMID:
30234374
7.

Exenatide.

Bridges A, Jacobs TF.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Aug 2.

8.
9.

Pharmacological Signatures of the Exenatide Nanoparticles Complex Against Myocardial Ischemia Reperfusion Injury.

Zhang Y, Qian P, Zhou H, Shen R, Hu B, Shen Y, Zhang X, Shen X, Xu G, Jin L.

Kidney Blood Press Res. 2018;43(4):1273-1284. doi: 10.1159/000492409. Epub 2018 Aug 3.

10.

Post hoc analysis of the Exenatide-PD trial-Factors that predict response.

Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Aviles-Olmos I, Chowdhury K, Skene SS, Limousin P, Foltynie T.

Eur J Neurosci. 2018 Aug 2. doi: 10.1111/ejn.14096. [Epub ahead of print]

PMID:
30070753
11.

Treatment with exenatide in acute ischemic stroke trial protocol: A prospective, randomized, open label, blinded end-point study of exenatide vs. standard care in post stroke hyperglycemia.

Muller C, Cheung NW, Dewey H, Churilov L, Middleton S, Thijs V, Ekinci EI, Levi C, Lindley R, Donnan G, Parsons M, Bladin C.

Int J Stroke. 2018 Oct;13(8):857-862. doi: 10.1177/1747493018784436. Epub 2018 Jul 18.

PMID:
30019627
12.

Effects of the multilayer structures on Exenatide release and bioactivity in microsphere/thermosensitive hydrogel system.

Wang P, Li Y, Jiang M.

Colloids Surf B Biointerfaces. 2018 Nov 1;171:85-93. doi: 10.1016/j.colsurfb.2018.04.063. Epub 2018 May 1.

PMID:
30015142
13.

Exenatide.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

14.

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.

Johansen NJ, Dejgaard TF, Lund A, Vilsbøll T, Andersen HU, Knop FK.

BMJ Open. 2018 Jun 27;8(6):e021861. doi: 10.1136/bmjopen-2018-021861.

15.

A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.

Pereira MJ, Lundkvist P, Kamble PG, Lau J, Martins JG, Sjöström CD, Schnecke V, Walentinsson A, Johnsson E, Eriksson JW.

Diabetes Ther. 2018 Aug;9(4):1511-1532. doi: 10.1007/s13300-018-0449-6. Epub 2018 Jun 13.

16.

Enhancing Stability of Exenatide-Containing Pressurized Metered-Dose Inhaler Via Reverse Microemulsion System.

Li X, Huang Y, Huang Z, Ma X, Dong N, Chen W, Pan X, Wu C.

AAPS PharmSciTech. 2018 Aug;19(6):2499-2508. doi: 10.1208/s12249-018-1026-z. Epub 2018 Jun 11.

PMID:
29948981
17.

Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease.

Li S, Wang X, Zhang J, Li J, Liu X, Ma Y, Han C, Zhang L, Zheng L.

Braz J Med Biol Res. 2018;51(8):e7299. doi: 10.1590/1414-431x20187299. Epub 2018 Jun 14.

18.

Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway.

Shao N, Yu XY, Ma XF, Lin WJ, Hao M, Kuang HY.

Gastroenterol Res Pract. 2018 Apr 15;2018:1864307. doi: 10.1155/2018/1864307. eCollection 2018.

19.

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.

Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Skene SS, Chowdhury K, Aviles-Olmos I, Limousin P, Foltynie T.

J Parkinsons Dis. 2018;8(2):247-258. doi: 10.3233/JPD-181329.

PMID:
29843254
20.

Nonclinical safety and pharmacokinetics of Miglyol 812: A medium chain triglyceride in exenatide once weekly suspension.

Buss N, Ryan P, Baughman T, Roy D, Patterson C, Gordon C, Dixit R.

J Appl Toxicol. 2018 Oct;38(10):1293-1301. doi: 10.1002/jat.3640. Epub 2018 May 28.

PMID:
29806696

Supplemental Content

Loading ...
Support Center